Compare Revvity Inc (RVTY) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Skyworks Solutions Inc — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while Skyworks Solutions Inc trades at $76.59 (market cap $12.15B). The key difference: Revvity Inc is the larger of the two by market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Skyworks Solutions Inc for 50 Days on average.
| RVTY | SWKS | |
|---|---|---|
Market Cap | $16.98B | $12.15B |
Volume | 1,456,900 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $157.36 | $91.45 |
52-Week Low | $82.26 | $52.50 |
Typical Hold Time | 12 Days | 50 Days |
Enterprise Value | $19.30B | $12.03B |
Dividend Yield | 0.18% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Skyworks Solutions (SWKS) trades at $76.35, down 8.49% in the last session, reflecting near-term pressure despite beating earnings estimates in recent quarters. The stock exhibits a bearish technical signal, with key support at $76, while fundamentals show declining revenue and net income margins over recent years. The pending merger with Qorvo represents a significant strategic development, aimed at enhancing scale and market diversification.
The investment outlook is mixed, with analyst consensus leaning bullish (60% buy ratings) and a price target of $78.80 offering modest upside. However, risks include execution challenges from the merger, competitive pressures in semiconductors, and ongoing profitability declines. The stock's current valuation at a P/E of 41.84 appears elevated relative to earnings growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
